BLIS settles patent issue, extends BSP agreement

BLIS Technologies has announced the settlement of a patent issue and the renegotiation of a five-year supply agreement with Bluestone Pharma (BSP).

The agreement, which was scheduled to expire this month, has now been extended.

The company said the negotiations between BLIS and BSP regarding the patent applications filed by BSP have concluded, with both parties agreeing to jointly own the patent applications.

This development provides certainty of access for BLIS and its licensees to the technology developed by BLIS, BSP, and Lactosan.

As part of the arrangement, BLIS, BSP, and Lactosan have released each other from all claims and causes of action arising from the publication of the patent applications.